Summary
Abbott Laboratories filed an 8-K report on July 16, 2014, to announce its second-quarter 2014 financial results. The primary focus of this filing is the disclosure of these results, which are provided in a press release furnished as Exhibit 99.1. Investors should note that Abbott utilized non-GAAP financial measures in its earnings announcement, adjusting for items such as cost reduction initiatives, tax law changes, repatriation of ex-U.S. earnings, and resolution of prior tax positions, as well as excluding intangible amortization expense. Management believes these non-GAAP measures offer enhanced visibility into the company's ongoing operational performance and are used internally for performance monitoring. However, Abbott advises investors to consider these non-GAAP figures in conjunction with, and not as a replacement for, standard GAAP financial measures. This filing serves as the official notification of the quarterly results and the associated financial reporting practices.
Key Highlights
- 1Abbott Laboratories announced its second-quarter 2014 financial results via an 8-K filing dated July 16, 2014.
- 2The press release detailing the Q2 2014 results is furnished as Exhibit 99.1 to the 8-K.
- 3The company employed non-GAAP financial measures in its earnings announcement.
- 4Non-GAAP adjustments include cost reduction initiatives, tax law changes, repatriation of ex-U.S. earnings, and resolution of prior tax positions.
- 5Intangible amortization expense was excluded from non-GAAP measures to provide clearer operational performance insights.
- 6Abbott's management uses these non-GAAP measures internally to assess business performance.
- 7Investors are cautioned to consider non-GAAP measures alongside GAAP financial measures.